Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Peter Thuss‐Patience, Alexander Stein, Eray Goekkurt et al.|Journal of Clinical Oncology|2022Cited by 4